Table 2.
Focal Therapy Selection Criteria
| Study | Type | PSA Requirements | Gleason Score | Clinical Stage | Bx |
| (Mean ng/mL) | |||||
| Bahn et al16 | Cryo | All (4.95) | All | NR | Initial 6-8 cores, targeted bx after |
| Lambert et al17 | Cryo | All (6.00) | 6, 7 (3 + 4) | NR | 12 core bx |
| Ellis et al18 | Cryo | All (7.2) | All | T1 to T3N0M0 | NR (Retrospective) |
| Onik et al19 | Cryo | All (NR) | All | T1c — T2b | Ultrasound-guided bx |
| Muto et al20 | HIFU | All (5.36) | All | T1c to T2N0M0 | NR |
| El Fegoun et al21 | HIFU | ≤ 10 ng/mL (7.3) | ≤ 7 (no predominant | ≤ T2a | ≤ 3 positive bx, only 1 lobe |
| pattern 4) | |||||
| Ahmed et al22 | HIFU | ≤15 ng/mL (7.3) | 4 + 3 or less | ≤T2bN0M0 | TRUS-guided bx, then TPM |
bx, biopsy; Cryo, focal cryoablation; HIFU, high-intensity focused ultrasound; NR, not reported; PSA, prostate-specific antigen; TPM, transperineal prostate mapping; TRUS, transrectal ultrasound.